Business Context and Reporting Period
This Form 8-K is a current report filed by Virios Therapeutics, Inc. (trading symbol: VIRI) on November 1, 2022. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's continued listing status. Note: The input metadata referenced "Dogwood Therapeutics," but the filing text explicitly identifies the registrant as Virios Therapeutics, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on stock listing compliance.
Material Changes
- Stock Price Decline: The company received notice that its common stock closed below the minimum $1.00 per share requirement for 30 consecutive business days prior to November 1, 2022.
- Listing Status: The stock continues to trade on the Nasdaq Capital Market under the symbol "VIRI" despite the notice.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted an initial 180-day compliance period ending on May 1, 2023, to regain compliance.
- Regaining Compliance: Compliance can be achieved if the bid price closes at $1.00 or more for 10 consecutive business days before the compliance date.
- Delisting Risk: If the company fails to regain compliance by the deadline, it may qualify for a second 180-day period. Failure to comply during the second period could result in delisting.
- Appeal Process: The company may appeal a delisting determination to the Nasdaq Listing Qualifications Panel, though success is not guaranteed.
- Management Action: Management intends to monitor the closing bid price and may consider available options to regain compliance.
Investor Verification Checklist
- Verify the current trading price of VIRI to assess proximity to the $1.00 threshold.
- Monitor future 8-K filings for updates on compliance status or potential reverse stock splits.
- Review the company's cash position in recent 10-Q or 10-K filings to determine if capital raises are needed to support operations while addressing the listing issue.
- Check for any announcements regarding a second compliance period if the May 1, 2023, deadline is approached without resolution.